Showing results (261-270 of 412) with videos related to
Sort By:
Pageof 42
Proceedings of Spie--The International Society for Optical Engineering|May 27, 2021
Semi-Supervised Multi-Organ Segmentation through Quality Assurance SupervisionHo Hin Lee, Yucheng Tang, Olivia Tang, et al.Proceedings of Spie--The International Society for Optical Engineering|April 28, 2021
Outlier Guided Optimization of Abdominal SegmentationYuchen Xu, Olivia Tang, Yucheng Tang, et al.Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|September 27, 2023
Learning from the CO-CREATE project: A protocol for systems thinking across research (STAR)Cécile Knai, Natalie Savona, Diane Finegood, et al.Plants (Basel, Switzerland)|July 14, 2023
Highly Efficient CRISPR/Cas9 Mediated Gene Editing in <i>Ocimum basilicum</i> 'FT Italiko' to Induce Resistance to <i>Peronospora belbahrii</i>Marina Laura, Chiara Forti, Sara Barberini, et al.Eclinicalmedicine|June 17, 2025
Incident cytopenia and risk of subsequent myeloid neoplasm in age-related clonal hematopoiesis: a multi-biobank case-control studyJames Brogan, Ashwin Kishtagari, Robert W Corty, et al.Cancer Chemotherapy and Pharmacology|February 10, 2020
Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancerHani M Babiker, Mohammed Milhem, Joseph Aisner, et al.Cancer Chemotherapy and Pharmacology|March 28, 2020
Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancerHani M Babiker, Mohammed Milhem, Joseph Aisner, et al.Gene|May 19, 2020
Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemiaGretchen Johnston, Haley E Ramsey, Qi Liu, et al.Journal of Cellular Biochemistry|November 13, 2018
BET inhibitors reduce cell size and induce reversible cell cycle arrest in AMLSusu Zhang, Yue Zhao, Tiffany M Heaster, et al.Haematologica|May 2, 2024
Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to 3 months of imatinib therapy: final 5-year results from DASCERNJorge E Cortes, Qian Jiang, Jianxiang Wang, et al.Pageof 42